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C-reactive protein (CRP), a systemic marker of inﬂammation, is a risk factor for late life cognitive impairment and dementia,
yet the mechanisms that link elevated CRP to cognitive decline are not fully understood. In this study we examined the
relationship between CRP and markers of neuronal integrity and cerebral metabolism in middle-aged adults with intact cognitive
function, using proton magnetic resonance spectrocospy. We hypothesized that increased levels of circulating CRP would correlate
with changes in brain metabolites indicative of early brain vulnerability. Thirty-six individuals, aged 40 to 60, underwent
neuropsychological assessment, a blood draw for CRP quantiﬁcation, and 1H MRS examining N-acetyl-aspartate, myo-inositol,
creatine,choline,andglutamateconcentrationsinoccipito-parietalgreymatter.Independentofage,sexandeducation,serumCRP
wassigniﬁcantlyrelatedtohighercerebralmyo-inositol/creatineratio(F(4,31) = 4.74, P = 0.004),arelationshipwhichremained
unchanged after adjustment for cardiovascular risk (F(5,30) = 4.356, CRP β = 0.322, P = 0.045). Because these biomarkers are
detectable in midlife they may serve as useful indicators of brain vulnerability during the preclinical period when mitigating
intervention is still possible.
1.Introduction
Much evidence suggests that inﬂammatory conditions com-
mon in midlife such as obesity, atherosclerosis, and Type
II diabetes play an important role in the development of
dementia [1, 2]. Longitudinal studies have indicated that
low-grade systemic inﬂammation in middle age adds to the
risk of late-life cognitive impairment over and above the
risk assessment aﬀorded by disease (e.g., hypertension and
atherosclerosis) and lifestyle habits (e.g., smoking) [1, 3,
4]. In addition, increases in serum inﬂammatory markers
such as interleukin-6 (IL-6) and C-reactive protein (CRP)
have been shown to exacerbate cognitive decline in older
adults with metabolic syndrome, a condition deﬁned by
cooccurring obesity, hypertension, dyslipidemia, and hyper-
glycemia [2, 5]. The long-term use of anti-inﬂammatory
drugs(NSAIDS),ontheotherhand,hasbeenassociatedwith
a reduction in dementia risk [6–8], lending further support
to the idea that sustained activation of an inﬂammatory
immune response can foster neuronal vulnerability beyond
what is expected of normal aging.
With increasing age, inﬂammatory changes are appre-
ciable in the brain in the form of astrocyte proliferation
and the presence of activated microglia [9]. However, it is
still unclear in what capacity midlife inﬂammation initiates
detectable changes in the brain that, if left unchecked,
may progress or contribute to neurodegenerative conditions.
Such information will be invaluable as chronic subclinical
inﬂammation presents a potentially modiﬁable risk factor
for future cognitive decline and dementia. Early detection
of biomarkers linked to cognitive decline allows time for
mitigatingactiontobetaken,priortotheonsetofirreversible
clinical signs.2 Cardiovascular Psychiatry and Neurology
With this information as background, our goal was to
investigate the relationship between systemic inﬂammation
and cerebral metabolism in middle-aged adults with intact
cognitive function. Speciﬁcally, we examined the association
between serum levels of CRP and markers of neuronal
integrity, osmolarity, and glial proliferation measured by
magnetic resonance spectroscopy (1H MRS). To our knowl-
edge, this is the ﬁrst study to examine the relationship
between an inﬂammatory marker and cerebral metabolites
in cognitively healthy adults. As such, it oﬀers novel infor-
mation regarding the cooccurrence of increasing systemic
inﬂammation and changes in neurochemistry within a
middle-aged sample.
CRP is an acute phase protein released by hepatocytes in
response to increases in circulating inﬂammatory cytokines
[10]. CRP also serves as an activator of the complement
system, an immunological cascade that assists the innate
immune system by marking and destroying non-self anti-
gens. Activation of complement is thought to contribute
to the perpetuation of the inﬂammatory response and is
implicated in neurodegenerative processes [11].
Perturbations in the levels of certain cerebral metabolites
have been correlated with a variety of clinical conditions.
Two markers in particular have been directly linked to chan-
ges in cognitive functioning: N-acetylaspartate (NAA) and
Myoinositol (mI). NAA occurs exclusively in neurons
and oligodendrocyte-type-2 astrocytes [12] and is widely
regarded as a marker of neuronal viability, synaptic health,
and metabolism [13]. Higher levels of NAA are linked to
better cognitive test performance [14], and reduced levels
are associated with cognitive impairment following brain
injury[15]andneurodegenerativediseases[16].Myoinositol
(mI) is an organic osmolyte and purported glial marker
[17] .C h a n g e si nl e v e l so fm Ih a v eb e e ns h o w nt op r e s a g e
the onset of cognitive decline in conditions fostering neu-
roinﬂammation, such as HIV and Alzheimer’s disease [18–
21]. Elevations of mI levels in Alzheimer’s disease have been
interpreted as a sign of gliosis [22].
We hypothesized that increased levels of circulating CRP
would correlate with changes in brain metabolites indicative
of early brain vulnerability, such as lower levels of NAA
and/or higher levels of mI.
2.MaterialsandMethods
The study was approved by the Institutional Review Board of
the University of Texas at Austin, and all volunteers provided
written informed consent before enrollment. Participants
were required to complete a medical history interview in
which medical conditions and treatments were coded as
either present or absent based on participants’ self-report.
Participants then underwent a full neuropsychological eval-
uation and a general health assessment, including a fasting
blood draw for CRP. Visits were conduced on separate days
and participants completed the study within one month.
2.1. Participants. Participants between the ages of 40 and
60 were recruited through ﬂyers and newspaper advertise-
ments. Exclusion criteria included a history of neurological
disease (e.g., large vessel stroke, seizure disorder, Parkinson’s
disease, clinically signiﬁcant traumatic brain injury, multiple
sclerosis, or brain infection/meningitis), major psychiatric
illness (e.g., schizophrenia, bipolar disorder), substance
abuse (diagnosed abuse and/or previous hospitalization for
substance abuse), diabetes mellitus, serum CRP greater than
10mg/L, or MRI contraindications. One hundred and three
volunteers were screened; of these, 36 participants (14 men,
22 women) passed the initial screening process and were
included in the ﬁnal sample.
The mean (±SD) age of the sample was 49.7 ± 6.5y e a r s .
Themeaneducationlevelwas15.0±2.6years.Themeanfull-
scaleIQscorewas112.3±12.4,indicatinghighaverageglobal
cognitive functioning according to published norms [23].
Enrollees identiﬁed themselves as follows: 42% Caucasian,
39% Hispanic, 3% Asian, 11% African American, and 6%
Other.
2.2. Assessments
2.2.1. General Health Screening. Fasting blood concentra-
tions of glucose, triglyceride, HDL-cholesterol, and LDL-
cholesterol were determined using the standard enzymatic
technique. Arterial blood pressure was measured using a
standard oscillometric blood pressure monitor (VP-2000,
Colin Medical Instruments, San Antonio, TX) after at least
15 minutes of rest. Body Mass Index (BMI) was calculated
as weight in kilograms divided by the square of height
in meters. Since CRP is also a recognized cardiovascular
risk factor [24], and cardiovascular disease is known to
impact cognition [2, 25, 26], cardiovascular disease (CVD)
risk factors (including obesity, hypertension, dyslipidemia,
hyperglycemia, and history of smoking) were coded as
present or absent (1 or 0) based on the American Heart
Association recommendations for risk criteria [27]. These
r i s kf a c t o r sw e r et h e ns u m m e dt oc r e a t ea no v e r a l lC V D
risk score (range 0–5) that was included as a covariate in
subsequent analyses.
2.2.2. High Sensitivity C-Reactive Protein (CRP) Assay. A
3mL fasting blood sample was collected from the antecubital
vein by venipuncture. Serumwas separated within 2 hours of
the collection, and aliquots were stored at −80◦C until later
analysis. Prior to the analysis, the serum sample was diluted
100-fold. Serum concentration of CRP was measured using
high sensitivity human ELISA kits (Alpha Diagnostics, San
Antonio, TX) with a minimum detectable concentration of
0.35ng/mL.
2.2.3. Neuropsychological Evaluation. All participants com-
pleted a two-hour assessment battery including standard
clinical neuropsychological instruments with established
reliability and validity [28]. Neuropsychological measures
were grouped into one of ﬁve cognitive domains: (1) global
cognitive functioning, (2) language functions, (3) memory
functions (4) attention-executive-psychomotor functions,
and (5) visual-spatial abilities. The following test scores
were included in each domain, and raw total scores wereCardiovascular Psychiatry and Neurology 3
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Figure 1: Anatomic images with superimposed voxel borders indicating MRS volume in occipitoparietal grey matter.
utilized: (1) global: WASI Full Scale IQ [23] and Mini-
Mental State Examination (MMSE) [29]; (2) language:
WASI Vocabulary Subtest and Category Fluency for Animals
[30]; (3) memory: CVLT-II immediate recall, delayed recall,
recognition discrimination [31], Rey Complex Figure Test
(RCF) immediate recall, delayed recall, and recognition
discrimination [28]; (4) attention-executive-psychomotor
functioning: WAIS-III, Digit Span Subtest [32], Controlled
Oral Word Association Test, (COWAT) [33], Trail Making
Test A and B [34], and Grooved Pegboard-Dominant Hand
timetocompletion[35];(5)visual-spatialabilities:RCFcopy
and WASI Matrix Reasoning Subtest. Emotional functioning
was also assessed with the Beck Depression Inventory-II
(BDI) [36] and the Trait Anxiety Inventory (STAI-T) [37].
All tests were administered and scored by a trained research
assistant using standard administration and scoring criteria.
Participants’ raw test scores were converted to z-scores using
the study sample mean and standard deviation. Timed test
scores were multiplied by −1 so that higher scores indicate
better performance. Five composite cognitive domain z-
scores were calculated for each participant by averaging the
z-scores of all tests within that domain.
2.2.4. Neuroimaging. Structural imaging included a high-
resolution Spoiled Gradient Echo (SPGR) sequence (256 ×
256 matrix, FOV = 24 × 24cm2, 1mm slice thickness, 0
gap) anatomical scan of the entire brain in the sagittal plane.
1H MRS data for each participant were acquired in a single
session on a 3T GE Signa Excite MRI scanner equipped
with a standard head coil. Single voxel proton 1H MRS was
performed using the automated GE pulse sequence PROBE-
P, which is a point resolved spectroscopy (PRESS) sequence
with chemical shift selected (CHESS) water suppression. 1H-
MRS parameters were as follows: echo time/repetition time
(TE/TR) = 35/3000ms, 128 excitations, 5000Hz spectral
width, volume ∼6cm 3 from the occipitoparietal gray matter
(Figure 1). The region was chosen because spectroscopically
detectable alterations in its neurochemical composition are
well documented in disorders of cognition, in correspon-
dence with severity of cognitive dysfunction [22]. Commer-
cially available software, LCModel, was used to quantify and
separate the metabolite resonances from the macromolecule
background [38]. In line with standard clinical protocols,
the concentrations of NAA, choline containing compounds
(choline,phosphocholineandglycerophosphocholine,Cho),
myoinositol, and glutamate (Glu) were reported as ratios rel-
ative to creatine (Cr) [22, 39]. MRS data for all participants
in the ﬁnal sample met quality control criteria (Cramer-Rao
Lower Bounds for NAA, mI, Cho or Glu <12).
Within pathological conditions, the use of Cr as a stable
standard for comparison of other metabolites is debated,
as are the beneﬁts of reporting absolute versus fractional
quantities of metabolites. We opted to report metabolite
concentrations in ratio to Cr because our sample consists of
healthymiddle-agedindividuals,andbecauseratiosaremore
easily obtained during clinical scans and hence possess more
clinical utility.
2.3. Data Analyses. The relationship between CRP and the
1H MRS markers (NAA/Cr, Glu/Cr, Cho/Cr and mI/Cr)
was analyzed using a single multivariate multiple linear
regressionmodelwithallMRSparametersenteredinatonce.
Age, sex, and level of education were chosen as covariates
ap r i o r i ,since they are known to inﬂuence the risk of
cognitive vulnerability [40, 41]. Follow-up analyses of the
relationship between mI/Cr and CRP were conducted using
linear regression. All statistical analyses were performed
using SPSS 16.0 (SPSS Inc., Chicago, IL). A two-tailed-
alpha level of 0.05 was used as the criterion for statistical
signiﬁcance.4 Cardiovascular Psychiatry and Neurology
3. Results
3.1. Selected Subject Characteristics. Selected characteristics
of the subjects are reported in Table 1. Raw cognitive test
scores and standard deviations are reported in Table 2.
Descriptive statistical analyses revealed a cognitively normal,
ethnically diverse, and middle-aged sample, well representa-
tive of the population of the state of Texas based on 2000 US
census data for the state. Regression residuals were normally
distributed according to the Shapiro-Wilk test of normality
(Shapiro-Wilk > 0.95, P>0.95), and no transformations
were performed.
3.2. Demographics and Cardiovascular Risk in relation to
CRP and Cerebral Metabolism. CRP was not signiﬁcantly
related to age, sex, or education level. As expected, increased
CRP was signiﬁcantly related to CVD risk (r = 0.346,
P = 0.039). We quantiﬁed CVD risk as a 0–5 index score
based on the current presence of each of the following risk
factors: obesity, hypertension, dyslipidemia, hyperglycemia,
and history of smoking. Among cerebral metabolites, male
sex was correlated with higher mI/Cr (r = 0.44, P = 0.007).
No other cerebral metabolites reached statistical signiﬁcance
in relation to demographic variables. Similarly, no cerebral
metabolites were signiﬁcant relative to level of CVD risk.
Among the variables used to assess CVD risk, obesity and
elevated fasting glucose were each signiﬁcantly associated
with higher CRP (β = 2.310, t = 2.302, P = 0.028 and
β = 2.396, t = 2.091, P = 0.045, resp.), whereas a history of
smoking (β =− 0.472, t = 0.454, P = 0.653), dyslipidemia
(β =− 0.026, t =− 0.025, P = 0.981), and hypertension
(β =− 1.416, t =− 1.453, P = 0.157) were not.
3.3. Cognition in relation to CRP and Cerebral Metabolism.
We found no signiﬁcant relations between CRP and mea-
sures of global cognitive functioning (r =− 0.15, P = 0.92),
language (r =− 0.12, P = 0.77), memory (r =− 0.22,
P = 0.37), attention-executive-psychomotor functioning
(r =− 0.13, P = 0.35), or visual-spatial ability (r =− 0.13,
P = 0.90). Nor did we ﬁnd signiﬁcant relations between
NAA/Cr, Cho/Cr, Glu/Cr, or mI/Cr and any domain of
cognitive functioning. These ﬁndings were not surprising
considering our relatively young, cognitively intact sample
(average global cognitive function (FSIQ) = 112.3).
3.4. CRP in relation to Cerebral Metabolism. Relationships
between CRP and cerebral metabolism were examined by
multivariate multiple regression analyses adjusted for sex,
age, and years of education. In fully adjusted analyses, CRP
was positively associated with cerebral mI/Cr in the brain
(F(4,31) = 4.74, P = 0.004) but not with NAA/Cr (F(4,31)
= 0.99, P = 0.427), Cho/Cr (F(4,31) = 0.53, P = 0.715) or
Glu/Cr (F(4,31) = 1.64, P = 0.188). Coeﬃcients are reported
in Table 3. This relationship remained unchanged even after
adjustment for cardiovascular risk (F(5,30) = 4.356, CRP
β = 0.322, P = 0.045).
4. Discussion
We found that higher serum CRP, a sensitive marker of
systemic inﬂammation, was signiﬁcantly related to higher
cerebral mI/Cr concentrations in cognitively normal middle-
aged adults. This ﬁnding adds to the growing body of
literature relating CRP to neurochemical changes linked to
the development of cognitive impairment in later life [1, 25,
42–44]. It extends the previous literature by suggesting that
systemic inﬂammation is related to neurochemical changes
eveninmiddle-agedadultswithintactcognitivefunctioning.
We chose to examine CRP because it presents a stable,
easily obtained inﬂammatory marker that is not subject
to variation based on time of sampling or blood glucose
levels [45]. CRP is also a well-known risk factor for vascular
disease and endothelial dysfunction [27, 46–49], both of
which contribute to the rate and severity of cognitive decline
over the lifespan [50, 51]. Perturbations in cerebral mI/Cr,
an organic osmolyte and marker of glial proliferation [17],
have also been shown to precede the onset of cognitive
decline in conditions fostering immune activation and
neuroinﬂammation [18–21]. However, until now, no studies
have speciﬁcally looked for a correlation between cerebral
mI/Cr levels and systemic inﬂammation. Our results indicate
thatincreasedsystemicinﬂammationcovarieswithincreased
cerebralmI/Cr.Whileourstudydoesnotallowforinferences
regarding a mechanistic linkage between CRP and changes
in mI/Cr, it nonetheless highlights a potential relationship
between these two factors. Importantly, this relationship is
detectable in midlife, prior to clinically signiﬁcant changes in
cognitive status.
One explanation for the increased mI/Cr observed in
our sample could be increased brain water diﬀusion in
the presence of proinﬂammatory conditions. Because of its
degrading eﬀect on tissue integrity, inﬂammation has been
positively correlated with increased white matter diﬀusion
in neurodegenerative disease [52, 53], acute neuroinﬂam-
matory conditions [54], and normal aging [55]. In turn,
increased brain water diﬀusion has been linked to higher
levels of cerebral osmolytes including mI/Cr [20]. Systemic
inﬂammation and resultant endothelial dysfunction could
also contribute to proinﬂammatory conditions in the brain
[2, 47], leading to increased brain water diﬀusion and glial
accumulation of osmolytes such as mI/Cr [44]. CRP in
particular has been implicated in autotoxic cascades leading
to decreased endothelial integrity [56], which over time may
impair cerebrovascularautoregulation and negatively impact
cognition [57].
Although our sample consisted of healthy adults without
clinical signs of neuroinﬂammation, many of them were
positive for one or more cardiovascular risk factors (e.g.,
hypertension, obesity) associated with increased circulating
inﬂammatory markers and endothelial dysfunction. In par-
ticular, the mean BMI of our sample, 29.7 (SD = 5.6), is con-
sideredobeseaccordingtoclinicalguidelinesdeﬁningobesity
a saB M Ie q u a lt oo rg r e a t e rt h a n3 0k g / m 2 [58]. Abdominal
obesity has been linked to elevated levels of CRP [59] and is
understood as a causative factor for endothelial dysfunction
[60]. It is possible that the higher mean BMI observed in ourCardiovascular Psychiatry and Neurology 5
Table 1: Selected characteristics of the subjects.
Mean (SD) % Median Range
Gender
14 men
22 women
Age 49.7 (6.5) years
Education level 15.0 (2.6) years
Caucasian 42
Hispanic 39
African American 11
Other 6
Asian 3
BMI (kg/m2) 29.7 (5.6) 29.29 21–56
CRP (mg/L) 2.72 (2.8) 1.32 .0006–9.53
Hypertension 30.5 125/75 104/61–183/98
High LDL 55.5 108 42–236
Hyperglycemia 13.9 97 80–276
Smokers 5.6
Table 2: Cognitive characteristics of the subjects.
Test measures by domain Sample mean score
(SD) Total possible score
Global cognitive functioning
Mini-Mental Status Exam (MMSE) 28.4 (1.3) 30
Wechsler Abbreviated Scale of Intelligence (WASI) 112.3 (12.4) 95% is 149–160
Language
WASI Vocabulary Subtest 62.4 (10.4) 80
Category Fluency for Animals (Animals) 23.8 (5.5) 1-minute limit
Visual-spatial
Complex Figure Test (CFT-Copy) 30.9 (4.2) 36
WASI Matrix Reasoning Subtest 25.9 (4.9) 35 (12–44 yrs) or
32 (45–79 yrs)
Memory
California Verbal Learning Test (CVLT)
Immediate recall 5.4 (1.8) 16
Delayed recall 11.0 (3.2) 16
Recognition (Yes/No) 3.1 (0.8) −4t o4
Complex Figure Test (CFT)
Immediate recall 15.9 (5.3) 36
Delayed recall 15.4 (5.5) 36
Recognition discrimination 18.7 (4.1) 24
Attention-executive-psychomotor
Trail Making Test A, time in seconds (Trails A) 29.6 (8.9) 5-minute limit
Trail Making Test B, time in seconds (Trails B) 74.8 (28.9) 5-minute limit
Controlled Oral Word Association Test (COWAT) 36.4 (9.8) 3-minute limit
Grooved Pegboard, Dominant Hand, time in seconds (Pegs-D) 76.6 (14.8) No limit
WAIS-III Digit Span Subtest (Digit Span) 16.9 (4.2) 306 Cardiovascular Psychiatry and Neurology
Table 3: Multiple regression analyses depicting independent correlates of Ins/Cr, NAA/Cr, Glu/Cr, and Cho/Cr.
Model R2 (P value) Variable B βP value
95% CI
Lower
bound
95% CI
Upper
bound
Dependent variable:
Ins/Cr
(1) 0.379 (0.004) Sex 0.104 0.539 0.001 0.046 0.161
Age −0.002 −0.102 0.480 −0.006 0.003
Years of education 0.011 0.301 0.054 0.000 0.023
CRP 0.013 0.375 0.015 0.003 0.023
Dependent variable:
NAA/Cr
(2) 0.113 (0.427) Sex 0.021 0.107 0.545 −0.050 0.092
Age 0.005 0.293 0.097 −0.001 0.010
Years of education −0.005 −0.134 0.461 −0.019 0.009
CRP 0.000 0.009 0.958 −0.012 0.013
Dependent variable:
Glu/Cr
(3) 0.175 (0.188) Sex 0.067 0.209 0.226 −0.044 0.178
Age −0.005 −0.201 0.233 −0.014 0.004
Years of education 0.024 0.394 0.030 0.003 0.046
CRP 0.001 0.011 0.947 −0.019 0.020
Dependent variable:
Cho/Cr
(4) 0.064 (0.715) Sex 0.010 0.212 0.247 −0.007 0.028
Age 0.000 0.067 0.706 −0.001 0.002
Years of education −0.001 −0.080 0.666 −0.004 0.003
CRP 0.000 0.025 0.890 −0.003 0.003
sample is one factor contributing to endothelial dysfunction
and accompanying changes in the neurochemical milieu.
Additionally, the mean CRP value of our sample
(2.72mg/L) falls just below the high-risk category for car-
diovascular disease events according to the American Heart
Association[27].TheAmericanHeartAssociation’sCRPrisk
categories (<1.0mg/L = low, 1.0 to 3.0mg/L = average, and
>3.0mg/L = high) are based on CRP tertiles observed in
the adult population. The high-risk tertile has roughly twice
the relative risk of a cardiovascular disease event compared
to the low-risk tertile [27]. The mean CRP value obtained
for our participants, especially taken together with the high
mean BMI, indicates that our sample may be at greater
risk for decreased endothelial integrity and increased brain
water diﬀusion. However, it should be stressed again that
the correlation between elevated CRP and elevated mI/Cr
does not indicate a mechanistic linkage between the two, and
the explanations oﬀered for elevated mI/Cr in this sample
remain hypothetical.
A related explanation for increased mI/Cr in our sample
is increased blood brain barrier (BBB) permeability [61],
which may contribute to neuronal vulnerability and eventual
cognitive decline. Myoinositol accumulates preferentially in
astrocytes, which, together with endothelial tight junctions,
provide selective permeability of the BBB. BBB permeability
increases in the presence of inﬂammatory markers and
may lead to toxic elevations of intracellular calcium [62].
In our sample increased levels of mI/Cr could be inter-
preted as an early sign of astrocyte proliferation related to
impaired endothelial function and resultant osmotic stress
inresponse tolow-gradesystemicinﬂammation.Supportfor
this hypothesis comes from the upregulation of mI synthesis
in the presence of conditions causing BBB permeability,
such as trauma, carbon monoxide poisoning, demyelina-
tion, beta-amyloid deposits [63], and neuroﬁbrillary tangles
[64]. These conditions represent extreme events leading to
neuronal vulnerability and cell death and are not assumed
to be present in our sample. However, taken together, our
observed increases in mI/Cr and CRP could be viewed as two
early indicators of neuronal vulnerability similar to though
less extreme than the conditions above. Further support for
this hypothesis comes from evidence that elevated mI/Cr
precedes changes in the levels of other cerebral metabolites
in diseases marked by cognitive decline, such as Alzheimer’s
disease and other dementias [18].
The primary strength of our study was the thorough
characterization of our sample in terms of cognitive and
physiological functioning. The cognitive battery utilized in
the study examined multiple domains of cognitive func-
tioning and relied on at least two measures within eachCardiovascular Psychiatry and Neurology 7
domain. Assessments of metabolic and vascular health were
performed by trained researchers rather than relying on self-
reported medical history, which may contain unintentional
omissions and errors. External conﬁrmation of cognitive
and physiological health status has allowed us to interpret
our ﬁndings with greater conﬁdence, without the potentially
confounding eﬀects of underreported medical conditions or
cognitive disorders.
Thecross-sectionaldesignofourstudypreventsdetermi-
nation of a causal link between inﬂammation and increased
mI/Cr and demonstrates only that there may be a rela-
tionship between these two factors. It is highly likely that
multiple factors in addition to these contribute to cognitive
decline over the lifespan. Our small, well-educated sample
also limits the generalizability of our ﬁndings. Moreover,
we did not obtain any additional assessments of neuronal
integrity, such as Diﬀusion Tensor Imaging, white matter
hyperintensities, or additional markers of inﬂammation,
suchasIL-6.Futurelongitudinalstudiesbeginninginmidlife
and conducted with larger, randomly selected community
samples could help elucidate potential interactions between
systemic inﬂammation and neural metabolism and the
extent to which these factors predict cognitive decline.
Additionally, combining multiple measures of neuronal
health and multiple measures of inﬂammation would oﬀer
a more complete picture of the ways in which brain health
is aﬀected by systemic inﬂammation. Finally, we did not
quantify other conditions known to correlate with CRP
levels, such as alcohol consumption, stress, and sleep quality.
Future studies should further examine these variables as they
relate to CRP levels and changes in cerebral mI/Cr.
Abbreviations
CRP: C-reactive protein
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mI/Cr: the ratio of myo-inositol to creatine.
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